- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 12:46 | Trump expected to nominate Heidi Overton as new FDA commissioner | ||
| 11:46 | Andelyn Biosciences to develop GM2 gangliosidosis therapy | ||
| 10:46 | BeOne Medicines and partners renew Brukinsa access programme for CLL | ||
| Di | LEO outlays $435m for rights to Tanabe's rare disease drug for sun-induced pain | ||
| Di | Faeth's PIKTOR plus paclitaxel combo gains FDA fast track status | ||
| Di | Fulcrum Therapeutics and Slate Medicines sign merger agreement | ||
| Mo | Moving at the speed of pharma digitalisation: driving ROI from AI and digital tools | ||
| Mo | Sandoz targets industry patent void with $322m Henlius deal | ||
| Mo | Lantheus Holdings' Alzheimer's radiodiagnostic secures FDA approval | ||
| Mo | EMA validates Pfizer and Valneva's Lyme disease vaccine | ||
| Mo | FDA grants fast track status to Phanes' spevatamig for advanced BTC | ||
| Fr | Immunology specialist Khartis Therapeutics emerges from stealth with $95m | ||
| Fr | BMS secures FDA accelerated approval for Zenbexus in multiple myeloma | ||
| Fr | Xanadu and University of Alberta to develop quantum algorithms for cancer | ||
| Do | United global response to US childhood vaccine overhaul | ||
| Do | Akeso secures China NMPA authorisation for ivonescimab combo | ||
| Do | Eli Lilly cracks down on illicit weight loss drug trade with US lawsuits | ||
| Do | Remepy secures $36m funding for hybrid drug pipeline expansion | ||
| 12.08. | Investigational CRISPR therapy succeeds in patient with drug-resistant E. Coli | ||
| 12.08. | Infinimmune raises $75m with big pharma backing for atopic dermatitis drugs | ||
| 12.08. | Epicrispr, Vaderis secure pivotal study funding for rare disease assets | ||
| 12.08. | Mereo BioPharma and Sentynl Therapeutics sign licensing deal for alvelestat | ||
| 12.08. | Alfasigma signs agreement to acquire Nordic Group | ||
| 11.08. | Trump signs order that nearly halves childhood immunisation coverage | ||
| 11.08. | UK regulators greenlight Lilly's Foundayo, intensifying Novo competition |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.